Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2019-07-05 2019-04-10
Drug Identification Number 02430827 02430827
Brand name LINEZOLID INJECTION LINEZOLID INJECTION
Common or Proper name Linezolid Injection Linezolid Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients LINEZOLID LINEZOLID
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 300mL 300mL
ATC code J01XX J01XX
ATC description OTHER ANTIBACTERIALS OTHER ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2019-04-11 2019-04-11
Actual start date
Estimated end date 2019-06-28 2019-06-28
Actual end date 2019-07-04
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Replenishment inventories of our Linezolid Injection 2 mg/mL freeflex® Bag 300 mL will be available at all distribution centres effective July 4, 2019 Please note that the stockout date may vary by region; please check your local distribution centre for stock availability. Pfizer is an alternate supplier of Linezolid Injection 2 mg/mL Bag 300 mL and have been informed of our impending supply interruption.
Health Canada comments